Aurobindo Pharma Ltd Analyst Rating
based on 28 analysts
71.43%
Buy
14.29%
Hold
14.29%
Sell
Based on 28 analysts offering long term price targets for Aurobindo Pharma Ltd. An average target of ₹1537.14
Source: S&P Global Market Intelligence
Aurobindo Pharma Ltd Share analysis
Aurobindo Pharma Ltd price forecast by 28 analysts
Upside of23.60%
High
₹1930
Target
₹1537.14
Low
₹1225
Aurobindo Pharma Ltd target price ₹1537.14, a slight upside of 23.6% compared to current price of ₹1246.2. According to 28 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Aurobindo Pharma Ltd revenue growth forecast
Expected growth rate Q1, FY2026:19.99%
Forecast
Actual
Including amortisation and stock based compensations
Aurobindo Pharma Ltd EPS growth forecast
EPS estimate Q1, FY2026:42.91%
Forecast
Actual
Source: S&P Global Market Intelligence
Aurobindo Pharma Ltd Performance
Day's Low
Day's High
₹1,237.5₹1,254.8552 Week's Low
52 Week's High
₹958.5₹1,592
| Returns % | |
| 1 Month Return | -10.84 % |
| 3 Month Return | -19.11 % |
| 1 Year Return | + 22.33 % |
| Market Stats | |
| Previous Close | ₹1,243.65 |
| Open | ₹1,250.10 |
| Volume | 5.72L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹72,870.26Cr |
Aurobindo Pharma Ltd Key Statistics
| P/E Ratio | 20.31 |
| PEG Ratio | 0.94 |
| Market Cap | ₹72,870.26 Cr |
| P/B Ratio | 3.24 |
| EPS | 54.09 |
| Dividend Yield | 0.41 |
| Sector | Pharmaceuticals |
| ROE | 10.35 |
Aurobindo Pharma Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹72,870.26 Cr | 35.81% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| BUY | ₹14,467.33 Cr | -1.94% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| HOLD | ₹98,409.68 Cr | 56.62% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹61,710.00 Cr | 25.37% | 0.53 | NA | NA | |
| BUY | ₹40,338.96 Cr | 9.11% | 0.56 | ₹589 Cr | ₹3,453 Cr |
Aurobindo Pharma Ltd Mutual Fund Holdings
About Aurobindo Pharma Ltd
The company is well known for its top products such as antibiotics, anti-malarials, cardiovascular, and anti-diabetic drugs. Its popular brands include Aurolife, Aurocare, Aurochem, and Aurovit. Aurobindo Pharma is one of the largest manufacturers of generic drugs in India, with a presence in over 150 countries worldwide.
Share Price: ₹1246.20 per share as on 06 Dec, 2024 04:01 PM
Market Capitalisation: ₹72,870.26Cr as of today
Revenue: ₹7,646.21Cr as on September 2024 (Q3 24)
Net Profit: ₹816.95Cr as on September 2024 (Q3 24)
Listing date: 19 Oct, 1995
Chairperson Name: K Ragunathan
| Organisation | Aurobindo Pharma Ltd |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Aurobindo Pharma Ltd
Aurobindo Pharma Officials Under Investigation for Extortion - 06 Dec, 2024
Andhra Pradesh CID has issued a lookout notice against Aurobindo Pharma officials and a YSRCP MP for alleged extortion and coercion in a share acquisition case valued at Rs 3,600 crore. The investigation involves accusations of manipulating audits and threatening a businessman to sell shares at undervalued prices.Aurobindo Pharma Subsidiary Secures USFDA Approval - 05 Dec, 2024
Aurobindo Pharma's wholly-owned subsidiary, Eugia Pharma Specialities, has received USFDA approval to manufacture Pazopanib Tablets, a cancer treatment, with a market size of $106 million. The product is expected to launch in Q4 FY25.Aurobindo Pharma Addresses Market Concerns and Opportunities - 04 Dec, 2024
Aurobindo Pharma is highlighted by Investec for its product overlap with granules, while the company clarifies its non-involvement in Kakinada port operations amid controversy.Geojit Reaffirms Buy Rating for Aurobindo Pharma - 28 Nov, 2024
Geojit Financial Services maintains a BUY rating on Aurobindo Pharma with a target price of Rs 1,540, citing strong growth in key markets and a robust product pipeline. The company reported an 8% YoY revenue increase, driven by U.S. and European sales, and expects continued profitability with projected adjusted PAT growth of 12.6% YoY in FY25.Aurobindo Pharma Reports Strong Q2FY25 Performance - 27 Nov, 2024
Aurobindo Pharma's Q2FY25 consolidated revenue rose 8% YoY to Rs. 7,796 crore, driven by U.S. and European sales growth. EBITDA increased 11.6% YoY, with a revised target price of Rs. 1,540. The company maintains a BUY rating.Aurobindo Pharma Partners for Respiratory Product Development - 25 Nov, 2024
Aurobindo Pharma's US subsidiary has entered a $25 million collaboration with a global pharma major for developing respiratory products, sharing costs capped at $90 million. The partnership is expected to last 3-5 years, enhancing Aurobindo's market position.Aurobindo Pharma Partners for Respiratory Product Development - 23 Nov, 2024
Aurobindo Pharma's US subsidiary has entered a licensing agreement with a global pharma major to develop and commercialize respiratory products, sharing costs up to $90 million over three to five years.Aurobindo Pharma Signs MoUs for New Facilities - 22 Nov, 2024
Aurobindo Pharma, along with five leading pharmaceutical companies, has signed memorandums of understanding with the Telangana government to establish manufacturing facilities in Pharma City.Aurobindo Pharma Faces Scrutiny and Stock Pressure - 18 Nov, 2024
Aurobindo Pharma is under scrutiny from Andhra MLAs for alleged lapses in emergency services, while its stock struggles below key moving averages, indicating potential downside risk.Aurobindo Pharma Secures GMP Certification and Upgraded Rating - 13 Nov, 2024
Aurobindo Pharma has received a GMP compliance certificate for its biosimilars facility in Hyderabad. KR Choksey upgraded the stock rating to BUY with a target price of Rs 1,591, citing long-term growth potential.Aurobindo Pharma Achieves GMP Certification and Revenue Growth - 12 Nov, 2024
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received EU GMP certification for its biosimilars facility, paving the way for future approvals. The company also reported strong Q2FY25 revenue growth, reflecting positive performance despite some operational challenges.Aurobindo Pharma Reports Q2 Profit Growth - 11 Nov, 2024
Aurobindo Pharma's Q2 FY25 net profit rose 8.6% YoY to ₹817 crore, aided by strong sales, though QoQ profit declined by 11%. Revenue increased 8% YoY to ₹7,796 crore, but margins missed targets.Aurobindo Pharma Reports Q2 Profit Growth - 10 Nov, 2024
Aurobindo Pharma's Q2FY25 net profit rose 8.6% YoY to Rs 817 crore, driven by strong sales in Europe and growth markets. Revenue increased by 8% YoY to Rs 7,796 crore, with EBITDA margin improving. Despite a QoQ profit decline, the company remains optimistic about maintaining growth.Aurobindo Pharma Reports Strong Q2 FY25 Results - 09 Nov, 2024
Aurobindo Pharma's Q2 FY25 results show an 8.9% revenue increase to ₹7,796 crore and an 8.6% profit rise to ₹816.95 crore, despite sequential profit decline.Aurobindo Pharma Supports Telangana's Green Pharma City - 08 Nov, 2024
M Madan Mohan Reddy of Aurobindo Pharma praised Telangana's initiative for a pollution-free pharma city, emphasizing its potential to boost the pharmaceutical sector and the state's economy. The company plans to finalize its investment strategy soon.
Insights on Aurobindo Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 9 quarters, 5.79K Cr → 7.93K Cr (in ₹), with an average increase of 3.8% per quarter
- POSITIVE IMPACT
Promoter Holding Up
Promoters have increased holdings from 51.80% to 51.82% in Sep 2024 quarter
NO EFFECTAgainst Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 146.0% return, outperforming this stock by 58.1%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 63.2% return, outperforming this stock by 40.9%
NEGATIVE IMPACTPrice Dip
In the last 7 days, AUROPHARMA stock has moved down by -1.5%
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 16.73% to 16.59% in Sep 2024 quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 19.17% to 18.53% in Sep 2024 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 919.22 Cr → 817.38 Cr (in ₹), with an average decrease of 11.1% per quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 6.70% to 6.46% in Sep 2024 quarter
Aurobindo Pharma Ltd Financials
Index Inclusions
Aurobindo Pharma Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.82% | 0.03 | |
| Foreign Institutions | 16.59% | ||
| Mutual Funds | 18.53% | ||
| Retail Investors | 6.46% | ||
| Others | 6.61% | 17.96 |
Aurobindo Pharma Ltd Key Indicators
Aurobindo Pharma Ltd Valuation
Aurobindo Pharma Ltd in the last 5 years
Lowest (6.73x)
March 23, 2020
Today (20.31x)
December 5, 2024
Industry (57.40x)
December 5, 2024
Highest (27.59x)
December 21, 2023
Aurobindo Pharma Ltd Earnings and Dividends
Aurobindo Pharma Ltd Earnings Results
Aurobindo Pharma Ltd’s net profit jumped 7.95% since last year same period to ₹817.38Cr in the Q2 2024-2025. On a quarterly growth basis, Aurobindo Pharma Ltd has generated -11.08% fall in its net profits since last 3-months.
Read More about Earnings ResultsAurobindo Pharma Ltd Dividends February,2024
In the quarter ending December 2023, Aurobindo Pharma Ltd has declared dividend of ₹1.50 - translating a dividend yield of 0.36%.
Read More about Dividends
Aurobindo Pharma Ltd Technicals Summary
Bearish
Neutral
Bullish
Aurobindo Pharma Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Aurobindo Pharma Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Aurobindo Pharma Ltd shares.
Aurobindo Pharma Ltd (AUROPHARMA) share price today is ₹1246.2
Aurobindo Pharma Ltd is listed on NSE
Aurobindo Pharma Ltd is listed on BSE
- Today’s highest price of Aurobindo Pharma Ltd is ₹1254.85.
- Today’s lowest price of Aurobindo Pharma Ltd is ₹1237.5.
PE Ratio of Aurobindo Pharma Ltd is 20.31
PE ratio = Aurobindo Pharma Ltd Market price per share / Aurobindo Pharma Ltd Earnings per share
Today’s traded volume of Aurobindo Pharma Ltd(AUROPHARMA) is 5.72L.
Today’s market capitalisation of Aurobindo Pharma Ltd(AUROPHARMA) is ₹72870.26Cr.
| Aurobindo Pharma Ltd(AUROPHARMA | Price |
|---|---|
52 Week High | ₹1592 |
52 Week Low | ₹958.5 |
Aurobindo Pharma Ltd(AUROPHARMA) share price is ₹1246.2. It is down -21.72% from its 52 Week High price of ₹1592
Aurobindo Pharma Ltd(AUROPHARMA) share price is ₹1246.2. It is up 30.02% from its 52 Week Low price of ₹958.5
| Aurobindo Pharma Ltd(AUROPHARMA | Returns |
|---|---|
1 Day Returns | 2.55% |
1 Month Returns | -10.84% |
3 Month Returns | -19.11% |
1 Year Returns | 22.33% |